Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 19/20 | 0.61 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099486 | 1.00 | PRKCQ (0.61) | PRKCQACACBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13999430 | 0.90 | PRKCQ (0.57) | PRKCQCYP3A4CYP2C9 | |
| SCHEMBL4697483 | 0.89 | PRKCQ (0.59) | PRKCQ | |
| SCHEMBL4697486 | 0.89 | PRKCQ (0.59) | PRKCQ | |
| SCHEMBL5095837 | 0.88 | PRKCQ (0.59) | PRKCQ | |
| SCHEMBL13999408 | 0.88 | PRKCQ (0.59) | PRKCQ | |
| SCHEMBL5099328 | 0.86 | PRKCQ (0.56) | PRKCQ | |
| SCHEMBL13999405 | 0.86 | PRKCQ (0.56) | PRKCQ | |
| SCHEMBL5102978 | 0.86 | PRKCQ (0.69) | PRKCQCYP3A4CYP2C9 | |
| SCHEMBL5102981 | 0.86 | PRKCQ (0.69) | PRKCQCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | PRKCQ, PRKCZ, PRKAR2B | PRKCQ 1/4885ACACB 1694/4885CYP1A2 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.